July 6, 2026 — The global neuroscience and emerging technology sectors are currently navigating a precipice of a new era as Brain-Computer Interface (BCI) clinical trials experience an unprecedented acceleration. According to recent industry data, the number of individuals with electrodes implanted in their brains has more than doubled since 2024, reaching an estimated 150 people globally, signaling that the nascent field of neural interfacing is officially transitioning from science fiction to clinical reality www.technologyreview.com .
The Corporate Race: From Neuralink to Neuracle
The confluence of corporate ambition and regulatory approval has created a fiercely competitive landscape. In January 2026, Neuralink announced that it has successfully implanted its device in 21 people over the past two years, demonstrating the viability of its high-channel-count threads for decoding motor intent www.technologyreview.com .
Simultaneously, Synchron is actively testing its minimally invasive Stentrode device in clinical trials across North America and Australia, obviating the need for open brain surgery by threading the electrode through the blood vessels www.technologyreview.com . Meanwhile, Precision Neuroscience, cofounded by a former Neuralink co-creator, is trialing a novel surface-based BCI that sits directly on the cortex without penetrating the tissue www.technologyreview.com .
The Regulatory Watershed: China's Medical Approval
Perhaps the most consequential development this year is that China has become the first country to officially approve a BCI for medical use www.technologyreview.com . Shanghai-based Neuracle, which has been trialing its technology since late 2024, recently obtained regulatory clearance for the device to be utilized outside of strictly controlled clinical trials www.technologyreview.com . This paradigm shift establishes a new global benchmark for neural medical devices, forcing regulatory bodies in the US and Europe to accelerate their own approval frameworks.
Academic Triumphs and the BrainGate Legacy
Beyond the commercial entities, academic research continues to push the boundaries of what is neurologically possible. The UC Davis team, operating as part of the BrainGate research effort—a pioneering project that has been running for two decades—is leveraging these advanced implants to restore communication and mobility to patients with severe paralysis www.technologyreview.com .
According to Marieke Vansteensel, a leading researcher in the field, the current estimation of 150 implanted individuals globally is merely the beginning. As engineering advances allow for more features and higher bandwidth data transmission, the ability to decode complex cognitive states and sensory feedback is rapidly approaching commercial viability www.technologyreview.com .
The Bottom Line
The exponential growth of BCI trials is not merely a statistical anomaly; it is a definitive testament to the maturation of neural engineering. We are no longer asking if the human brain can interface directly with digital systems; we are now optimizing the bandwidth, biocompatibility, and regulatory pathways for a future where thought and action are seamlessly integrated.
For the emerging technology sector, the mandate is unequivocal: the biological barrier has been breached. The next decade will be defined not by the invention of the BCI, but by the ethical, clinical, and commercial scaling of the human-machine symbiosis.
Official Announcements & Resources
MIT Technology Review Coverage:
June 19, 2026 — Comprehensive analysis of the global surge in Brain-Computer Interface trials, detailing how the number of implanted individuals has doubled to 150, alongside updates from Neuralink, Synchron, Neuracle, and Precision Neuroscience. (Note: As specific daily social media posts from these entities for this aggregate milestone are not currently available for direct embedding, the official MIT Technology Review publication serves as the primary, authoritative source for this data).
Read the Full MIT Technology Review Article →